Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.Kevin Kalinsky, Seth A. Wander, Erika Hamilton et al.|Journal of Clinical Oncology|2024Cited by 75
Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancerLacey M. Litchfield, Iris L. Romero|Oncotarget|2015Cited by 39